Skip to main content

Aspira Women's Health Inc.

For the period ended Dec 31, 2024. Filed Mar 27, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 27, 2025

AWHL$0.430.0%Stored close · as of Sep 19, 2025

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 15. Exhibits and Financial Statement Schedules

ITEM 15.EXHIBITS, FINANCIAL STATEMENT SCHEDULES
(a)LIST OF DOCUMENTS FILED AS PART OF THIS REPORT:
1.Financial Statements

The financial statements and notes thereto, and the report of the independent registered public accounting firm thereon, are set forth on pages F-1 through F-29.

2.Financial Statement Schedules

All financial statement schedules have been omitted as the information is not required under the related instructions or is not applicable or because the information required is already included in the financial statements or the notes to those financial statements.

(b)EXHIBITS
Exhibit · Incorporated by Reference · Filed
NumberExhibit DescriptionFormFile No.ExhibitFiling DateHerewith
3.1Fourth Amended and Restated Certificate of Incorporation of Aspira Women’s Health Inc. dated January 22, 20108-K000-316173.1January 25, 2010
3.2Certificate of Amendment of Fourth Amended and Restated Certificate of Incorporation, effective June 19, 201410-Q001-348103.2August 14, 2014
3.3Certificate of Amendment to Fourth Amended and Restated Certificate of Incorporation of Vermillion, Inc. dated June 11, 20208-K001-348103.1June 11, 2020
3.4Certificate of Amendment to Fourth Amended and Restated Certificate of Incorporation of Aspira Women’s Health Inc, dated February 7, 20238-K001-348103.1February 7, 2023
3.5Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock8-K001-348104.1April 17, 2018
3.6Amended and Restated Bylaws of Aspira Women’s Health Inc., effective February 23, 20228-K001-348103.1February 28, 2022
3.7Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of Aspira Women’s Health Inc., as amended May 11, 20238-K001-348103.1May 11, 2023
4.1Form of Aspira Women’s Health Inc.’s (formerly Ciphergen Biosystems, Inc.) Common Stock CertificateS-1/A333-328124.1August 24, 2000
4.2Securities Purchase Agreement dated May 8, 2013, by and among Aspira Women’s Health Inc. (formerly Vermillion, Inc.) and the purchasers identified therein8-K001-3481010.1May 14, 2013
4.3Stockholders Agreement dated May 13, 2013, by and among Vermillion, Inc., Oracle Partners, LP, Oracle Ten Fund Master, LP, Jack W. Schuler and other purchasers named therein8-K001-3481010.2May 14, 2013
4.4Amended and Restated Promissory Note #1 by Vermillion, Inc. in favor of the State of Connecticut, acting by and through the Department of Economic and Community Development, effective April 3, 202010-K001-348104.4April 7, 2020
4.5Amended and Restated Promissory Note #2 by Vermillion, Inc. in favor of the State of Connecticut, acting by and through the Department of Economic and Community Development, effective April 3, 202010-K001-348104.5April 7, 2020
4.6Form of IndentureS-3333-2522674.7January 20, 2021
4.7Description of Aspira Women’s Health Inc.’s Securities Pursuant to Section 12 of the Securities Exchange Act of 193410-K001-348104.7April 1, 2024
4.8Form of Warrant 20228-K001-348104.1August 24, 2022
4.9Form of Warrant Amendment to Common Stock Purchase Warrant_20228-K001-348104.3January 26, 2024
4.10Form of Pre-Funded Warrant 20248-K001-348104.1January 26, 2024
4.11Form of Warrant 20248-K001-348104.2January 26, 2024
4.12Form of Common Warrant June 20248-K001-348104.1July 2, 2024
4.13Form of Warrant July 20248-K001-348104.1July 31, 2024
4.14Form of Warrant Amendment to Common Stock Purchase Warrant June 2024√
4.15Form of Senior Convertible Note8-K001-348104.1March 11, 2025
4.16Form of Warrant8-K001-348104.2March 11, 2025
4.17Form of Securities Purchase Agreement8-K001-3481010.1March 11, 2025
10.1Securities Purchase Agreement, dated July 20, 2023, by and between Aspira Women’s Health Inc. and the purchasers identified therein8-K001-3481010.1July 24, 2023
10.2Form of Aspira Women’s Health Inc Stock Option Award Agreement #10-Q001-3481010.4August 10, 2022
10.3Form of Aspira Women’s Health Inc Restricted Stock Award Agreement #10-Q001-3481010.5August 10, 2022
10.4Aspira Women’s Health Inc. 2019 Stock Incentive Plan #10-Q001-3481010.3August 10, 2022
10.5Form of Aspira Women’s Health Inc. Stock Option Award Agreement (non-employee) #10-Q001-3481010.7August 10, 2022
10.6Assistance Agreement by and between the State of Connecticut, acting by and through the Department of Economic and Community Development and Vermillion, Inc. effective March 22, 201610-Q001-3481010.1May 16, 2016
10.7Patent Security Agreement by Vermillion, Inc. in favor of the State of Connecticut, acting by and through the Department of Economic and Community Development, effective March 22, 201610-Q001-3481010.3May 16, 2016
10.8Security Agreement by Vermillion, Inc. in favor of the State of Connecticut, acting by and through the Department of Economic and Community Development, effective March 22, 201610-Q001-3481010.4May 16, 2016
10.9First Amendment to the Assistance Agreement by and between the State of Connecticut, acting by and through the Department of Economic and Community Development and Vermillion, Inc. dated March 7, 201810-K001-3481010.21March 13, 2018
10.10Second Amendment to the Assistance Agreement by and between the State of Connecticut, acting by and through the Department of Economic and Community Development and Vermillion, Inc. dated April 3, 202010-K001-3481010.22April 7, 2020
10.11 · Consulting Agreement between Aspira Women’s Health Inc. and Nicole Sandford effective December 16, 2024 # † · √
10.12License Agreement between Aspira Women’s Health Inc. and Dana-Farber Cancer Institute, Inc. effective March 20, 202310-K001-3481010.28April 1, 2024
10.13Form of Securities Purchase Agreement June 20248-K001-3481010.1July 2, 2024
10.14Form of Warrant Inducement Agreement June 20248-K001-3481010.1July 31, 2024
10.15At The Market Agreement between Aspira Women’s Health Inc. and H. C. Wainwright & Co., LLC dated August 2, 20248-K000-316171.1August 2, 2024
19.1Aspira Women’s Health Inc. Insider Trading Policy√
21.0Subsidiaries of Registrant10-K001-3481021.0March 31, 2022
23.1Consent of BDO USA, P.C., Independent Registered Public Accounting Firm√
24.1Power of Attorney (included on signature page hereto)√
31.1Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002√
31.2Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002√
32.1Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002√
97.1Aspira Women’s Health Incentive Compensation Recoupment Policy10-K001-3481097.1March 29, 2024
101Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language (“Inline XBRL”)
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
√Filed herewith
#Management contract or compensatory plan or arrangement.
†Confidential treatment has been granted with respect to certain provisions of this agreement. Omitted portions have been filed separately with the SEC.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.